Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Cedar Pollen Allergy Therapeutic Pipeline Market Review, H2 2016

Monday, October 31, 2016 0:01
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Cedar Pollen Allergy – Pipeline Review, H2 2016’, provides an overview of the Cedar Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


Request a sample report @


- The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
- The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Complete report details @



Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Report Coverage 5
Cedar Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Cedar Pollen Allergy – Overview 7
Pipeline Products for Cedar Pollen Allergy – Comparative Analysis 8
Cedar Pollen Allergy – Therapeutics under Development by Companies 9
Cedar Pollen Allergy – Therapeutics under Investigation by Universities/Institutes 10
Cedar Pollen Allergy – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Cedar Pollen Allergy – Products under Development by Companies 14
Cedar Pollen Allergy – Products under Investigation by Universities/Institutes 15
Cedar Pollen Allergy – Companies Involved in Therapeutics Development 16
ALK-Abello A/S 16
Astellas Pharma Inc. 17
Circassia Pharmaceuticals Plc 18
Immunomic Therapeutics, Inc. 19
Japan Tobacco Inc. 20
REGiMMUNE Corporation 21
Cedar Pollen Allergy – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ASP-4070 – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Biologic for Cedar Pollen Allergy – Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
JCC-LAMP-Vax – Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
RGI-1001 – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine – Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
TO-206 – Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Vaccine for Cedar Pollen Allergy – Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Vaccine for Japanese Cedar Pollen Allergy – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Cedar Pollen Allergy – Dormant Projects 42
Cedar Pollen Allergy – Product Development Milestones 43
Featured News & Press Releases 43
Aug 07, 2015: ALK’s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet 43
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 43
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 43
Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 44
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 46
Disclaimer 47


Get It now @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)        

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.